Citations

Clear

2429 citation(s) found for "Shah, SS".

A Web‐Based Calculator for Hematopoietic Progenitor Cell Collections: App Development and Retrospective Assessment
Roth, Maxwell T. , Liu, Jun , Shah, Sanjana , Shao, Claire , Chen, Maria Y. , Haj, Amelia K. , Feeney, Dennis M., Munkacsy, Kendra, Christiansen, Nelya, Geary, Kristine, Sarhan, Suhayla, Callanan, Colleen, Ferrara, Stephanie, Covington, Mischa L. , Manis, John , Spitzer, Thomas R. , Brunker, Patricia A. R. , Grewal, Eric P , Covington, Mischa L , Chai, Li , Brunker, Patricia A R , Ruby, Kristen N , Grewal, Eric P. , Feeney, Dennis, Christiansen, Nelya, Ferrara, Stephanie, Stowell, Sean R. , Ruby, Kristen N.

Mayo Clinic

Journal of Clinical Apheresis | December 11, 2025 | Volume: 40 | Issue: 6 | Pages: No page available

10.1002/jca.70080 | PMID 41378729 Get It

ABSTRACT A major challenge in hematopoietic progenitor cell apheresis is determining the whole blood (WB) volume to process to achieve a CD34+ cell collection goal. We developed a web‐based calculator app that uses the Collection Efficiency 2 (CE2) model to estimate personalized WB processing volumes needed to reach a prescribed CD34+ cell collection goal. Retrospective evaluation of the app using collection data from two academic medical centers showed that actual processed WB volumes were frequently higher than the app's recommendations. The frequency of potential under‐collection events is predicted to be low had the app‐calculated volumes been utilized. Our findings suggest that using the app's recommendations may lower total WB processing volumes, reducing over‐collection and time spent on the apheresis machine, while maintaining a low under‐collection risk profile.
PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors
Brown, Sherry‐Ann , Fang, Michelle , Sparapani, Rodney , Osinski, Kristen , Taylor, Bradley , Yu, Duo , Blessing, Jeffrey, Shah, Rushabh , Collier, Patrick , Bagherimohamadipour, Mehri , Zhang, Jun , Kothari, Anai N. , Rickards, John , Otto, Cameron, Sanchez, Zanele, Arruda‐Olson, Adelaide M. , Cheng, Yee Chung , Fang, Michelle Z , Osinski, Kristen , Taylor, Bradley , Shah, Rushabh , Collier, Patrick , BagheriMohamadiPour, Mehri , Kothari, Anai , Echefu, Gift , Rickards, John , Olson, Jessica , Arruda-Olson, Adelaide, Cheng, Yee Chung , Cheng, Feixiong , Zhou, Yadi

Mayo Clinic

Journal of the American Heart Association | December 11, 2025 | Volume: 14 | Issue: 24 | Pages: No page available

10.1161/jaha.123.030363 | PMID 41378455 Get It

Background Cardiovascular disease (CVD) is a leading cause of death in cancer survivors. Predicting CVD risk in this population remains challenging. Risk prediction models that use machine learning algorithms could provide an objective method for accurate risk prediction to facilitate the prevention and management of CVD in cancer survivors. We evaluated previously tested machine learning algorithms and logistic regression (regularized by machine learning methods), in addition to testing and validating newer, more complex machine learning algorithms, for CVD prediction in cancer survivors. Methods This multicenter study used a database of 3835 multiracial cancer survivors with 89 clinical, laboratory, and echocardiographic features over 20 years. Models were trained using repeated random and time‐split samples and tested on a separate cohort of 329 patients. Model performance was assessed using the area under the receiver operating characteristic curve. Results Regularized logistic regression achieved an area under the receiver operating characteristic curve of 0.845 (heart failure), 0.783 (atrial fibrillation), 0.792 (coronary artery disease), and 0.806 (composite CVD). These are comparable to 0.837 and 0.848 for heart failure, using Bayesian additive regression tree and random forest as more advanced machine learning models, respectively. De novo composite CVD (post‐cancer diagnosis) was also predicted with an area under the receiver operating characteristic curve of 0.826 using regularized logistic regression, compared with 0.735 and 0.802 using decision tree and random forest, respectively. Conclusions Regularized logistic regression and advanced machine learning models demonstrated similar predictive performance, with institutional transferability. These tools may support risk stratification and prevention strategies in cardio‐oncology using longitudinal data. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05377320.
Evaluating the Statistical Robustness of Randomized Controlled Trials of Spinal Cord Stimulation for Pain through the Use of Fragility Index
Hussain, Nasir , Brull, Richard , Shah, Raghav , Bozer, Jordan, D’Souza, Ryan S. , Weaver, Tristan, D'Souza, Ryan S , Karri, Jay , Prokop, Larry J. , Abdallah, Faraj W.

Mayo Clinic

Anesthesiology | December 11, 2025 | Volume: 144 | Issue: 4 | Pages: 898-912

10.1097/aln.0000000000005876 | PMID 41376548 Get It

Background: The use of spinal cord stimulation (SCS) for managing severe refractory chronic pain has expanded considerably due to positive statistical evidence regarding its use; however, the statistical robustness of the underlying randomized controlled trials (RCTs) requires further scrutiny. One such tool that can be used for this purpose is the fragility index, which quantifies how many individual outcome events must be altered for an outcome to lose statistical significance. Thus the index can be used quantitatively to assess the stability and robustness of an RCT’s conclusions, with higher values indicating increased trial stability. This study assesses the fragility of pain outcomes across RCTs investigating SCS for chronic pain to better understand the quality and robustness of evidence. Methods: A systematic search was conducted for RCTs assessing SCS for any chronic pain indication. The primary outcome was an evaluation of the trial-specific fragility index for the prespecified pain primary outcomes of RCTs. Secondary outcomes included an evaluation of fragility for (1) specified indications for SCS therapy, (2) reported pain outcomes appearing in three or more RCTs, (3) the presence/absence of a conflict of interest, and (4) comparisons of SCS to conservative management or different SCS waveform modalities. Results: A total of 30 RCTs were included. The median (interquartile range [IQR]) fragility index across the primary outcome of all trials was 5.45 (3.00 to 11.45). There was no statistical difference between the (1) types of outcomes (dichotomous vs. continuous; P = 0.710), (2) primary versus secondary pain outcomes ( P = 0.771), or (3) presence versus absence of trial conflict of interest ( P = 0.753). Indications with a median (IQR) fragility score greater than three included persistent spinal pain syndrome type 2 with a score of 8.00 (2.80 to 12.60), painful diabetic neuropathy with a score of 6.00 (3.00 to 11.80), complex regional pain syndrome with a score of 7.20 (4.62 to 81.50), mixed etiologies with a score of 9.00 (3.00 to 38.00), and other etiologies with a score of 3.00 (1.00 to 8.55). Conclusions: This study suggests that the majority of RCTs investigating primary pain outcomes after SCS therapy are robust with relatively high fragility scores. Reporting the fragility of outcomes in trials can provide a more comprehensive assessment of trial robustness and can further aid clinicians in interpreting trial results and making informed treatment decisions.
Immune checkpoint inhibitor-induced diabetes leading to distress and worsening quality of life: A case report
Saey, Stephanie , Sara, Jaskanwal Deep Singh , Shah, Pankaj

Mayo Clinic

No container title available | December 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8149829/v1 Get It

Abstract An 86-year-old woman with metastatic non-small cell lung carcinoma on Pembrolizumab presented to the Emergency Department with diabetic ketoacidosis; after appropriate treatment she was transitioned to basal/bolus insulin regimen. She had chosen to receive Immune Checkpoint Inhibitor (ICI) instead of radiotherapy, as she wished to preserve her quality of life. With the demands of management of ICI-induced irreversible insulin deficient diabetes she now has substantial worsening of quality of life with considerable anxiety and depressed mood. ICI-induced diabetes and DKA is more common in patients treated with Pembrolizumab than suggested by early trials. In addition to highlighting the importance of counseling patients on the signs and symptoms of hyperglycemia for earlier detection, our case calls for considering the psychological impact of managing a chronic illness in patient education prior to initiating ICI therapy.
Foundations of systems-based hematology: thematic analysis of expert interviews to guide curriculums and promote growth
Godby, Richard , Cogan, Jacob C. , Cuker, Adam , García, David , Masias, Camila , May, Jori E. , Morton, Colleen , Shah, Surbhi , Zumberg, Marc , Marshall, Ariela L. , Godby, Richard Curtis , Lim, Ming Y , May, Jori , Schaefer, Jordan K , Shah, Surbhi , Zumberg, Marc S , Marshall, Ariela , Schaefer, Jordan K.

Mayo Clinic

Blood Advances | December 5, 2025 | Volume: 10 | Issue: 6 | Pages: 2038-2046

10.1182/bloodadvances.2025018748 | PMID 41348898 Get It

Abstract Systems-based hematology (SBH) is an emerging discipline focused on optimizing care delivery for patients with hematologic disorders within complex health care systems. Despite its growing importance, the field lacks a formal definition, standardized curriculum, and clear career pathway, hindering widespread adoption and training of future SBH experts. We sought to define core principles, competencies, challenges, and future directions of SBH to identify foundational components for a potential educational curriculum. Semistructured interviews were conducted with 8 SBH experts. Expert participants were identified through their committee involvement with the American Society of Hematology. Five overarching themes emerged: (1) The accidental expert: SBH careers have developed organically and reactively in response to pressing institutional needs, not through formal training; (2) Defining the unseen: experts define the field pragmatically by its function and roles; (3) The SBH toolkit: success requires a hybrid skillset combining clinical hematology expertise with health systems science (HSS) principles; (4) The architect's dilemma: the field's growth is hindered by interdependent challenges of building a curriculum, awareness, and securing resources; and (5) Charting the future: the discipline is poised for growth, driven by increasing health care complexity and specialization. SBH represents the nexus of HSS principles and hematology care. Formalizing SBH requires a multipronged approach, including developing a standardized curriculum that equips learners with a hybrid skillset, creating clear value for health systems and patients, and fostering a community of practice through professional societies. These findings provide a foundational framework for developing educational resources and institutional support necessary to continue advancing SBH.
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Alexander, Jessie L. , Saldaña, Blachy J. Dávila , Brazauskas, Ruta , Dammalapati, Sravya Gethika, Griffith, Linda M. , Shah, Ami J. , Shimano, Kristin A. , Ochs, Hans D., Bleesing, Jack , Ebens, Christen L. , Kapadia, Malika, Bauchat, Andrea , Oved, Joseph H. , Eissa, Hesham, Lust, Hannah , Haines, Hilary , Rayes, Ahmad , Madden, Lisa, Shereck, Evan , Miller, Holly, Martinez, Caridad , Rozmus, Jacob, Yu, Lolie C. , Chellapandian, Deepak , Aquino, Victor M., Knutsen, Alan P. , Chong, Hey , Chopek, Ashley, Gillio, Alfred P. , Joshi, Avni Y. , Rangarajan, Hemalatha G. , Andolina, Jeffrey R. , Lugt, Mark T. Vander , Prockop, Susan E. , Shyr, David C. , Sullivan, Kathleen E. , Weinacht, Katja G. , Torgerson, Troy R. , Marsh, Rebecca , Dvorak, Christopher C. , Heimall, Jennifer , Leiding, Jennifer W. , Puck, Jennifer M. , Rawlings, David J. , Cowan, Morton J. , Petrović, Aleksandra , Pai, Sung‐Yun , Burroughs, Lauri M. , Dávila Saldaña, Blachy J , Oved, Joseph H , Lust, Hannah , Rayes, Ahmad , Forbes Satter, Lisa R , Bednarski, Jeffrey J , Chellapandian, Deepakbabu , Joshi, Avni, Rangarajan, Hemalatha G , Andolina, Jeffrey R , Prockop, Susan E , Parikh, Suhag , Torgerson, Troy R , Chan, Alice Y , Haddad, Elie , Pulsipher, Michael A. , Leiding, Jennifer W , Kohn, Donald B , Puck, Jennifer M , Notarangelo, Luigi D , Pai, Sung-Yun , Burroughs, Lauri M , Ebens, Christen L , Dvorak, Christopher C , Shimano, Kristin A , Shah, Ami J , Ochs, Hans D., Kapoor, Neena R. , Keller, Michael D. , Chandrakasan, Shanmuganathan , Talano, Julie‐An , Satter, Lisa Forbes , Moore, Theodore Bruce , DeSantes, Kenneth B , Parikh, Suhag , Haddad, Élie , Kohn, Donald B.

Mayo Clinic

Blood Advances | December 5, 2025 | Volume: 10 | Issue: 5 | Pages: 1783-1798

10.1182/bloodadvances.2025017662 | PMID 41346295 Get It

Abstract Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT and mismatched donors are known to affect overall survival (OS). However, the influence of specific clinical manifestations or WAS variant class on OS and factors associated with event-free survival (EFS) remain incompletely defined. We analyzed outcomes of 308 patients with WAS who underwent HCT at 37 institutions of the Primary Immune Deficiency Treatment Consortium from 1990 to 2018. With a median follow-up of 5.3 years, the 5-year OS and EFS were 87.2% and 79.7%, respectively. Age ≥5 years, donor type, and a pre-HCT history of severe infection had a negative impact on OS and EFS, whereas pre-HCT autoimmunity had no impact. Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non–busulfan-based regimens were used. Low myeloid donor chimerism was associated with lower platelet counts. Mixed chimerism was not consistently associated with post-HCT autoimmunity. Patients with class I (exon 1-2 missense and intron 5 hot spot variants) and class II variants (all others) had similar pre-HCT clinical symptom severity and no difference in OS, EFS, or platelet recovery post-HCT. In conclusion, our study showed excellent long-term OS and EFS after HCT for WAS, highlighting the importance of early HCT, before the development of severe infections. We confirmed that HCT using busulfan-based conditioning was associated with improved donor chimerism and platelet recovery. This trial was registered at www.clinicaltrials.gov as NCT02064933.
Prevalence and demographics of autoimmune hemolytic anemia in the United States
Knoll, Christopher , Jackson, Louis , Choudhry, Zia , Shah, Surbhi , Krumme, Alexis A. , Godby, Richard , Blacketer, Clair

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6239-6239

10.1182/blood-2025-6239 Get It

Abstract Background: Autoimmune hemolytic anemia (AIHA) is a condition in which the immune system erroneously attacks and damages red blood cells. While the epidemiology of AIHA has been examined in various European and Asian nations (Hansen 2020; Kao 2025), there is limited data available from the United States (US). Using US insurance claims data, this research aimed to determine the prevalence and demographic characteristics of AIHA over a five-year span. Methods: Five databases were used: Merative MarketScan Commercial Claims and Encounters; Optum's de-identified Clinformatics® Data Mart Database; Closed and Open claims sourced through HealthVerity; Merative MarketScan Medicare Supplemental Database; Merative MarketScan Multi-State Medicaid. AIHA was defined by ICD-10 diagnosis codes D59.1x in a given calendar year and a second code within 365 days prior. Annual prevalence in years 2019 – 2023 was calculated among people with insurance enrollment for at least 6 months in the calendar year. Annual prevalence was stratified by age group, sex, and prescription fill for an AIHA-related treatment (systemic steroids, immunosuppressants [azathioprine, mycophenolate, cyclosporin, cyclophosphamide, danazol, bortezomib, rituximab], splenectomy) in the calendar year. Extrapolation of prevalence rates for commercial and government assistance insurance to the US population for 2023 was implemented by age and sex-standardization to the US Census population. For data sources that included both commercial and government assistance insurance, patients aged <65 years were analyzed as commercial insurance and aged ≥65 years as government assistance. Results: AIHA prevalence in 2023 across databases ranged from 2.7 to 4.3 per 100,000 for ages <18 years; 4.2 to 9.4 per 100,000 for ages 18 – 34 years; 8.2 to 11.8 per 100,000 for ages 35 – 49 years; 15.4 to 23.9 per 100,000 for ages 50 – 64 years; 26.6 to 37.0 per 100,000 for ages 65 – 74 years; and 30.6 to 61.2 per 100,000 for age 75 years and older. Across databases and over time, the proportion of AIHA patients that were female was 55% – 67%. Across all databases, in year 2023, half (44% - 55%) of patients received any AIHA-related treatment, out of which one third (26%-34%) received systemic steroids, less than one quarter (9% – 17%) received rituximab, and one third (25% – 31%) received a different immunosuppressant. Compared to patients with commercial insurance, Medicaid-insured patients had lower AIHA-related treatment utilization, whereas Medicare-insured patients had higher utilization. Within age group and sex and by insurance type, low and high estimates of prevalence were used to define a range of prevalence. After standardization to the 2023 US Census population, the estimated prevalence in 2023 ranged from 38,459 to 57,235 patients diagnosed with AIHA, corresponding to prevalence rates of 11.6 to 17.3 per 100,000. This marked an increase from 2019 US Census-standardized estimates of 32,777 to 48,482, with corresponding prevalence rates of 10.1 to 14.9 per 100,000. Discussion: AIHA prevalence was higher in older age groups, with a peak prevalence in ages 65 and older. Prevalence increased approximately 15% over a 5-year interval and was notably higher in patients with commercial health insurance compared to government insurance programs, which may in part be due to the older age of the Medicare population. Fewer than half of patients received an AIHA-related treatment in 2023, which could reflect heterogeneity in disease severity necessitating treatment, in addition to the relapse-remitting nature of AIHA whereby patients experience remission for periods of time. Additionally, insurance claims do not specify an indication for treatment nor a reason for discontinuation; some treatments could have been prescribed for an underlying condition contributing to AIHA. Finally, prevalence extrapolation assumes Americans without health insurance are diagnosed with AIHA at the same rate as those with insurance, which may slightly overestimate the total number of diagnosed patients.Conclusion: AIHA prevalence in this study was consistent with estimates from European countries and has been increasing in recent years, providing evidence of consistent disease epidemiology across several geographies.
Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study.
Hamid, Muhammad Saad , Mehta-Shah, Neha, Akkad, Neha , Orlando, Evelyn, Ruan, Jia , Abro, Brooj , Flowers, Christopher R. , Pongas, Georgios , Allen, Pamela B. , McCook‐Veal, Ashley A. , Switchenko, Jeffrey M. , Mehta–Shah, Neha , Malpica, Luis , Wallace, Danielle, Larson, Melissa C. , Cerhan, James R. , Mou, Eric , Bennani, N. Nora

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1870-1870

10.1182/blood-2025-1870 Get It

Abstract Introduction: CTCLs are rare, heterogeneous non-Hodgkin lymphomas (NHL) with significant regional variability in treatment patterns. Prospective studies characterizing CTCL management, particularly in racially and ethnically diverse populations, remains limited. The LEO-MER multi-center prospective cohort study (NCT02736357) is designed to address the persistent disparities in outcomes research by enrolling historically underrepresented groups of patients diagnosed with lymphoma across the United States (US). Here, we present a real-world analysis of CTCL patients that reflects US academic practice, evaluating treatment patterns, as well as prognostic factors influencing survival outcomes. Methods: Patients aged ≥18 years with newly diagnosed CTCL were prospectively enrolled in either the University of Iowa/Mayo Clinic MER cohort (2002-2015) or the expanded LEO cohort (2015-2020), which included 8 US academic centers. Standardized protocols were used to abstract clinical, pathologic, treatment, and outcome data from medical records. ANOVA/Kruskal-Wallis and Fisher's/chi-square tests were used to compare patient distribution across demographic and clinical characteristics based on data distribution and sample size. Overall survival (OS) was calculated from diagnosis to death or last follow-up. Survival analyses employed Kaplan-Meier estimation supplemented by Cox proportional hazards modeling. Results: The LEO-MER cohort enrolled 223 CTCL patients (91 MER and 132 LEO). Subtypes included mycosis fungoides (MF, n=155, 69.5%), Sézary syndrome (SS, n=22, 9.9%), primary cutaneous anaplastic large-cell lymphoma (n=17, 7.6%), subcutaneous panniculitis-like T-cell lymphoma (n=11, 4.9%), cutaneous CD4+ small/medium T-cell lymphoproliferative-disorder (n=9, 4%), and other rarer CTCL subtypes (n=9, 4%). Among the MF/SS cohort, median age was 64 years (Range: 18-89 years), 58.2% (n=103) were male and race/ethnicity distribution included White (n=123, 69.5%), Black (n=29; 16.4%) and others/unknown (n=25; 14.1%). Stage distribution included 62.7% with early-stage (ES) MF (IA-IIA, n=111), 37.2% with advanced-stage (AS) MF (IIB-IVB, n=66). To complete diagnostic workup, T-cell receptor (TCR) testing was performed in 52.6% of skin biopsies (n=92) and 62.5% of blood samples (n=110), with clonal detection rates of 75% (69/92) in skin and 51.8% (57/110) in blood. Paired TCR matching between skin and blood samples was performed in 31.6% (n=56) of cases, demonstrating 53.6% (30/56) concordance. Blood flow cytometry data were reported in 80.1% (89/111) and 84.4% (56/66) of ES and AS MF cases, with T-cell population being detected in 7.2% (8/111) and 62.1% (41/66) of ES and AS cases. Nodal biopsies were obtained in 23.4% (n=41) of patients and clonality assessment was reported in 18.6% (33/177) of these cases. The MF/SS cohort's lifetime treatment exposure data (n=160) revealed topical skin-directed therapies alone (n=49, 31.8%) as the most common approach followed by lifetime exposure to topical skin-directed and systemic therapies (n=45, 29.2%) followed by multimodal exposure of topical skin-directed, radiation and systemic treatments (n=30, 19.5%). Only 5.6% of patients were enrolled in a clinical trial. First-line (1L) systemic regimens were predominantly a) immunomodulatory agents (n=47, 29.3%); including oral retinoid (n=20), extracorporeal photopheresis (n=18), interferon (n=9) followed by b) chemotherapy (n=30, 18.7%) and c) targeted therapies (n=17, 10.6%) including Brentuximab Vedotin (n=6), Romidepsin (n=5), Mogamulizumab (n=3), Vorinostat (n=2) and Pralatrexate (n=1). Multivariable analysis predicting 1L systemic treatment initiation demonstrated a significant association with presence of N2/N3 stage (N2/N3 vs N0/N1: Odds Ratio (OR): 5.45) and elevated LDH (OR: 5.30). At median follow-up of 91.1 months (mon), median OS was 122.3 mon (95% confidence interval 67.2-159.2 mon). In subset analyses, Black race (p=0.001) and SS (p=0.0001) were associated with worse OS outcomes. Conclusion: We present initial data from our prospective LEO-MER cohort, a large US-based multicenter consortia. Our findings demonstrate variability in both diagnostic staging and treatment approaches for MF/SS patients. The cohort demonstrated worse outcomes with high-risk disease and Black race/ethnicity. These findings warrant further study on the impact of underlying social determinant factors, given the variability noted in this population.
CSF3R-mutated chronic neutrophilic leukemia: A two-center study of 44 consecutive patients
Caron-L'Ecuyer, Janick, Al‐Kali, Aref , Hogan, W. Michael, Foran, James M. , Reichard, Kaaren K. , He, Rong , Gangat, Naseema , Mendoza, Cinthya, Elliott, Michelle A. , Pardanani, Animesh , Tefferi, Ayalew , Bolarinwa, Abiola , Szuber, Natasha , Hogan, William, Shah, Meera , Badar, Talha

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2013-2013

10.1182/blood-2025-2013 Get It

Abstract Introduction: CSF3R mutations (CSF3RMUT), most commonly T618I, represent the defining genomic alteration in chronic neutrophilic leukemia (CNL), present in ~80% of cases. Despite emerging real-world data, information on treatment outcomes and prognostic factors remains limited due to rarity of the disease. In this two-center retrospective study, we examined clinical and molecular predictors of treatment response, overall survival (OS), and blast transformation (BT) and outcome following allogeneic stem cell transplant (ASCT). Methods: The study was approved by the institutional review boards of the Mayo Clinic (USA) and the University of Montreal (Canada). Electronic medical records were reviewed to identify patients with CSF3R mutated CNL at both institutions and extract relevant data. Statistical analyses were conducted using JMP Pro 17.0.0 software (SAS Institute, Cary, NC, USA). Results: Forty-four patients (68% male, median age 68 years [range: 26-93]) were included. At diagnosis, 20 (56%) were asymptomatic, 13 (36%) presented with constitutional/non-specific symptoms, and 20 (50%) had antecedent leukocytosis at a median of 13 months(mo) prior. Splenomegaly (palpable or radiological) was observed in 28 (67%) patients, hepatomegaly in 7 (17%) and lymphadenopathy in 4 (9.8%). Median white blood cell count (WBC) was 52×10⁹/L (range: 17-390). CSF3RMUT/variants included 39 (89%) with T618I (7 of the 39 had additional CSF3RMUT), 2 (5%) with M696T, and 1 (2%) each for I598I, Q739* and T640N. Frequent co-mutations included ASXL1 in 25 (63%) patients, SETBP1 in 14 (36%), and SRSF2 in 8 (31%), with overlapping occurrence; 10 (38%) patients had ≥2 of these 3 mutations. Ten patients (median WBC 29 x10⁹/L [range: 19–58]), were initially observed without treatment for a median of 8.6 mo; 2 remained on observation alone at 46 and 77 mo. Hydroxyurea (HU) alone or in combinations excluding ruxolitinib (Ruxo) was the most common first-line treatment (68%). Second-line therapies included Ruxo (39%), HU (25%), and hypomethylating agents (14%). WBC response (≥50% reduction from baseline) was 78% with HU vs. 60% with Ruxo (p=0.2). WBC response to HU was lower with abnormal karyotype (40% vs. 94%; p=0.02). WBC response to Ruxo was lower with SETBP1MUT (0% vs. 72%; p=0.05) and with male sex (40% vs. 100%; p=0.04). Seven patients underwent ASCT, including 2 after BT; four (57%) of the 7 remain alive, including 2 without evidence of disease (both 45 mo post-ASCT; one harbored ASXL1MUT) and the other 2 with active disease (both harbored ASXL1MUT). Three patients died from veno-occlusive disease (Day+34), CNS relapse with AML (at 105 mo post-ASCT), or unrelated causes (at 44 mo post-ASCT). Median OS was longer in transplanted patients (115 vs 23 mo; p=0.03). At a median follow-up of 44 mo for living patients, disease transformation occurred in 10 patients, including 7 with BT (6 with T618I, 1 T640N) and 3 with chronic myelomonocytic leukemia (2 M696T, 1 T618I). BT rate at 2, 3, and 5 years was 15%, 31%, and 43%, respectively. Univariate analysis (UVA) identified male gender (p<0.01), >5% immature WBCs (p=0.02), platelets <160×10⁹/L (p=0.04), higher WBC (p=0.02), and ASXL1 or SETBP1 mutation (p<0.01) as risk factors for BT. On multivariable analysis (MVA), only the latter remained significant. Median OS was 26 mo (95% CI: 21-43) for the entire cohort; 24 mo for patients with T618I CSF3RMUT vs 53 mo with other CSF3RMUT, p=0.1. In UVA, age >60 years (HR 5.0, p=0.03), platelets <160×10⁹/L (HR 3.4, p=0.006), WBC >50×10⁹/L (HR 2.6, p=0.02), and ASXL1 or SETBP1 mutations (HR 4.2, p=0.01) were associated with shorter OS. In MVA, age >60 (HR 6, p=0.03), WBC >50×10⁹/L (HR 12, p<0.01), and the presence of ASXL1MUT or SETBP1MUT (HR 9.5, p=0.01) remained significant. Based on the HRs on MVA, one adverse point was allocated for age >60 years, and two adverse points each for WBC >50×10⁹/L and presence of ASXL1 or SETBP1 mutations. Patients were accordingly stratified into low (0-2 points), intermediate (3) and high (4-5) risk groups with corresponding median OS of “not reached”, 29 mo, and 16 mo (p<0.01). Causes of death included disease progression (82%), infection/bleeding (9%), and ASCT complications (9%). Conclusion: The current study highlights the prognostic relevance of “SETBP1 or ASXL1” mutation for both overall survival and risk of blast transformation. The study also signifies variable natural history and potential benefit from ASCT.
Hematological symptom burden and treatment patterns in patients with IgG4-related disease: A real-world, multicenter retrospective analysis
Vojjala, Nikhil, Gillani, Syed Fahad, Shah, Rushi, Kotla, Nikhil Kumar, Mahadevia, Himil, Valasapalli, Srijan, Krishnamoorthy, Geetha, Singh, Vijendra, Vojjala, Nikhil, Gillani, Syed Fahad, Shah, Rushi, Kotla, Nikhil Kumar, Mahadevia, Himil, Valasapalli, Srijan, Krishnamoorthy, Geetha, Singh, Vijendra

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4479-4479

10.1182/blood-2025-4479 Get It

Abstract Background: IgG4-related disease (IgG4-RD) is a rare, immune-mediated fibroinflammatory condition characterized by tissue infiltration with IgG4-positive plasma cells. While solid organ involvement is well documented, data on hematologic manifestations and associated outcomes remain limited. Understanding hematological burden and real-world treatment patterns is essential to guide comprehensive management. Methods: We conducted a multicenter, retrospective cohort study using the TriNetX Research Network, comprising electronic health records from multiple U.S. healthcare systems. Adults (≥18 years) with a diagnosis of IgG4-RD (ICD-10 codes) were included. Patients with a prior diagnosis of hematologic malignancy were excluded. Demographic characteristics, hematologic manifestations, treatment patterns, and overall mortality were assessed. The median follow-up duration was 519 days. Results: A total of 2,596 patients with IgG4-RD were identified, of whom 554 (21.3%) exhibited at least one hematologic manifestation. The mean age was 58.1 ± 15.9 years; 53% were male (n=1,379), and 57% were White (n=1,492). Hypertension was the most common comorbidity (44%, n=1,136). Among those with hematologic involvement, key manifestations included lymphadenopathy (n=605, 23.3%), hepatomegaly (n=114, 4.4%), splenomegaly (n=73, 2.8%), eosinophilia (n=71, 2.7%), pancytopenia (n=31, 1.2%), hypergammaglobulinemia (n=71, 2.7%), and monoclonal gammopathy (n=86, 3.3%). Regarding outcomes, 127 of 2,596 patients (4.9%) died during the follow-up period. Among those with hematologic manifestations, 36 of 554 (6.5%) died, indicating a numerically higher mortality rate in this subgroup. Treatment data revealed that all patients received corticosteroids as initial therapy. Additionally, 531 patients (20.4%) received steroid-sparing immunosuppressants. The most used agents included rituximab (6%), azathioprine (6%), mycophenolate mofetil (5%), and methotrexate (3%). Conclusion: In this large, real-world cohort of patients with IgG4-RD, hematologic manifestations were observed in over one-fifth of patients and were associated with a numerically higher mortality rate. Lymphadenopathy was the most common hematologic feature. Despite the widespread use of corticosteroids, a substantial proportion of patients required steroid-sparing agents. These findings highlight the hematologic complexity of IgG4-RD and underscore the need for multidisciplinary management and prospective studies focused on hematologic outcomes.